Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX
Theodoros Michelakos(Harvard University), Cristina R. Ferrone(Cedars-Sinai Medical Center), Kim C. Honselmann(University Hospital Schleswig-Holstein), Andrew L. Warshaw(Harvard University), Carlos Fernández‐del Castillo(Massachusetts General Hospital), Motaz Qadan(Massachusetts General Hospital), Aparna R. Parikh(Massachusetts General Hospital), Vikram Deshpande(Beth Israel Deaconess Medical Center), Theodore S. Hong(Massachusetts General Hospital), Keith D. Lillemoe(Harvard University), Janet E. Murphy(Harvard University), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Lei Cai(Army Medical University), Ryan David Nipp(Harvard University), Jill N. Allen(Harvard University), Ilaria Pergolini(TUM Klinikum)
Cited by 326
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k